Summit Therapeutics (NASDAQ:SMMT – Get Free Report) and Cosmos Health (NASDAQ:COSM – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.
Volatility and Risk
Summit Therapeutics has a beta of -1.36, meaning that its stock price is 236% less volatile than the S&P 500. Comparatively, Cosmos Health has a beta of 5.33, meaning that its stock price is 433% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Summit Therapeutics and Cosmos Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Summit Therapeutics | 2 | 5 | 8 | 2 | 2.59 |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
Institutional and Insider Ownership
4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 12.6% of Cosmos Health shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 25.1% of Cosmos Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Summit Therapeutics and Cosmos Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Summit Therapeutics | N/A | N/A | -$1.08 billion | ($1.45) | -13.37 |
| Cosmos Health | $54.43 million | 0.21 | -$16.18 million | ($0.75) | -0.41 |
Cosmos Health has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Summit Therapeutics and Cosmos Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Summit Therapeutics | N/A | -296.82% | -250.96% |
| Cosmos Health | -31.01% | -33.19% | -13.65% |
Summary
Cosmos Health beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
